Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BioPharmX logo — company profile

BioPharmX

Founded 2011 United States San Jose, United States 6 employees Series A Total: $20.37M Biotechnology, Health Care

General Information

Company Name BioPharmX
Founded Year 2011
Location United States San Jose, United States
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with BioPharmX. To contact BioPharmX, visit biopharmx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioPharmX compare?

A PDF of BioPharmX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioPharmX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioPharmX

BioPharmX Corporation is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. The company, founded in 2011 and headquartered in the United States, is developing prescription products through its proprietary HyantX™ delivery system for dermatology indications. BioPharmX has two lead products in development, with BPX-04 for the treatment of papulopustular rosacea and BPX-01 for the treatment of acne vulgaris. The organization secured a $7.87M Series A investment on 18 March 2015. Although the last investment round did not disclose the specific investors, BioPharmX's focus on addressing unmet dermatology needs with proprietary delivery systems presents an opportunity for growth and potentially disruptive innovation within the biotechnology and healthcare industries.

Business keywords: pharmaceuticals, drug delivery, dermatology, biotech, prescription products, chronic dermatologic conditions, HyantX™ delivery system, papulopustular rosacea, acne vulgaris, health and wellness markets, Silicon Valley executives, biotech expertise, regulatory expertise, molecular properties, OTC applications

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $7.87M -
18 Mar 2015
Series A $12.00M 1
Korea Investment Partners
Korea Investment Partners
10 Nov 2014
Debt Financing $500.00K -
03 Jan 2014

BioPharmX Alternatives & Competitors

View All Alternatives
BioPharmX vs
Novan, Inc.
Novan, Inc. United States

Novan, Inc. is a medical dermatology company primarily focused on researching, developing and commer...

Post-IPO Debt
45 employees
Biotechnology, Health Care
BioPharmX vs
Visterra Inc.
Visterra Inc. United States

We bring better biologics to life. Biospace Best Place to Work 2024!

Series C
139 employees
Biotechnology, Health Care
BioPharmX vs
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. United States

Harnessing beneficial bacteria to treat chronic inflammatory skin conditions.

Convertible Note
6 employees
Biopharma, Biotechnology
View all alternatives

FAQ About BioPharmX

BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. The Company is developing prescription p...
BioPharmX was founded in 2011.
BioPharmX is headquartered in San Jose, United States.
BioPharmX operates in Biotechnology and Health Care. Its work centres on pharmaceuticals, drug delivery, dermatology and biotech.
BioPharmX has approximately 6 employees.
BioPharmX has completed 3 funding rounds, raising a total of $20.37M. The latest funding stage is Series A.
Top alternatives and competitors to BioPharmX include Novan, Inc., Visterra Inc., MatriSys Bioscience, Inc., NextCure, Inc., Zogenix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioPharmX and Novan, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioPharmX, https://bouncewatch.com/company/biopharmx, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout